Refine search

Tumour Site

605 results for ""

Suresh Ramalingam

How long should we give immunotherapy for?

The length of immunotherapy course for metastatic lung cancer was arbitrarily set at 2 years in clinical trials, but definitive studies investigating the optimum duration against the risk-benefit profile are lacking

By Suresh Ramalingam
Lesley Seymour receives the TAT Honorary Award 2022

Lesley Seymour receives the TAT Honorary Award 2022

In her keynote lecture at the ESMO Targeted Anticancer Therapies Congress 2022, Prof. Lesley Seymour stresses the importance of sharing ideas and resources between academia and industry 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.